### **Overview** Amrutanjan Health Care Limited (AHCL), founded in 1893, is a leading Indian over-the-counter (OTC) healthcare company headquartered in Chennai, Tamil Nadu. With a legacy of 132 years, AHCL combines Ayurvedic principles with modern science to deliver fast-acting, trusted wellness solutions. The company operates across core categories: **Head & Body Pain Management**, **Women’s Hygiene (Comfy)**, and **Rehydration (Electro+)**. It ranks among the top 20 OTC companies in India and is targeting ₹1,000 crore in revenue, having grown from ₹100 crore in 2012 to nearly ₹500 crore today. AHCL’s product portfolio includes: - **Amrutanjan Pain Balms & Roll-Ons** (flagship yellow and white balms, roll-ons, sprays) - **Comfy Sanitary Napkins**, **Tampons**, and **Menstrual Cups** - **Electro+** (ORS and electrolyte drinks) - Derma care products (e.g., Stop Itch Anti-Fungal Spray) - Oral care (Stop Pain Dental Gel) The company serves markets across India and in 13 countries in the Middle East, Africa, Southeast Asia, and Asia, with a physical presence in Dubai and plans to enter the US and European consumer markets. --- ### **Strategic Growth Focus (Nov 2025 Update)** AHCL’s growth strategy centers on three pillars: 1. **Market Penetration:** Expanding reach in existing P1 (metros, Tier 1) and developing P2/P3 (rural, underserved) markets. 2. **Product Innovation:** Launching new formats and premium products across key categories. 3. **Category Expansion:** Strengthening leadership in high-growth segments like body pain relief, feminine hygiene, and daily hydration. Key growth drivers: - Increasing **Amrutanjan brand penetration in P1 markets** - Developing **P2 markets** through rural van sales, wall paintings, and direct distributor networks - Introducing **new pain relief formats** (roll-ons, sprays, low-MRP packs) - Expanding **Comfy’s outlet reach from 500,000 to 1 million in 3 years** --- ### **Recent Developments & Initiatives (Aug 2023 – Nov 2025)** #### **1. Women’s Hygiene: Comfy Brand Acceleration** - **Comfy Revenue:** Achieved ₹130 crore in FY2025; grew at 18% YoY in FY2025. - **Market Position:** Holds 3% national volume share; **27% share in Odisha**. - **Product Expansion:** Launched **Comfy Slimfit XXL 310mm Night Pads** (Oct 2025), **Slim Fit**, **Cottony**, **XL**, **Ultra XL**, **Tampons**, and **Menstrual Cups**. - **Distribution:** Reaches ~500,000 outlets, with 60% in **rural India** — highlighting strong rural penetration. - **Growth Metrics:** Brand awareness, consideration, and usage improved YoY; XL variant grew **59% annually**. - **Private Label Partnership:** Contributed to FY2025 revenue success. - **School Sampling:** Reached 250,000 female students in 720 schools (FY24) to promote menstrual hygiene. #### **2. Manufacturing & Supply Chain Upgrades** - **New Sanitary Napkin Plant:** A **dedicated, state-of-the-art, 2.5 million pads/day facility in Hyderabad** to be commissioned by **Q4 2025**. - Fully automated, cGMP-compliant - Expected to increase **gross margins from 33% to 40%** - Enhances **supply chain control**, scalability, and responsiveness - **Current Production:** Sourced via partnership with **TZMO (Poland)**, but moving toward **in-house captive manufacturing by Q4 FY26**. #### **3. Pain Management Innovation & Expansion** - **Category Performance:** - Pain management grew **6% in FY2025**, led by small SKUs and roll-ons. - **Body pain sub-segment** grew **19.6% (volume)** in FY2025; contributes ₹50 crore (15% of pain sales). - **Goal:** Triple body pain revenue to **₹150 crore by FY2028**. - **New Launches (Sep 2025):** - **Amrutanjan Faster Relaxation Roll-On (AFRR) 2.5ml** at ₹20 — affordable, on-the-go solution. - Launched in **hanger format** to boost in-store visibility and drive impulse purchases. - Expanded into **grocer channel** to increase access in lower-tier towns. - **JIFFY Re-launch (Nov 2025):** Introduced **Diclofenac-based topical products** to strengthen presence in body pain segment. #### **4. Rehydration Segment: Electro+ Growth** - **Electro+ Positioning:** A holistic hydration brand with **50% daily Vitamin C**, real fruit juice base, and flavors (Apple, Orange, Lemon). - **Product Innovations (Aug 2025):** - Launched **Electro+ Tetra Pack (ready-to-drink)** and **Electro+ Powder (sachets)** with **WHO-recommended ORS formula**. - Introduced **Electro+ Rehydrate 160ml at ₹25** — affordable entry-level SKU. - **Growth:** Rehydration segment grew **10% in FY2025** despite regulatory headwinds and competition. - **Distribution:** Available in **70,000+ pharmacies**; growing as a daily wellness drink. #### **5. Marketing & Brand Campaigns** - **TV Campaign (Nov 2025):** High-impact media rollout for **Yellow & White Balms** and **Headache Roll-On**, highlighting **indoor/outdoor usage**. - **Digital Integration:** Highest **media investment allocation** this year; includes digital sampling, social media, and e-commerce visibility. - **Sports Partnerships:** - **Official Rehydration Partner** of the **Professional Golf Tour of India (PGTI)** - Extensive sampling at **marathons** and sports events to target active consumers. - **Brand Ambassador:** Cricketer **Ruturaj Gaikwad** appointed for **Electro+**, aligning with health, youth, and vitality. #### **6. Channel & Distribution Expansion** - **Direct Sales Force:** Covers ~9,800 towns, reaching **266,000+ outlets**. - **Project M5K:** Aims to onboard **5,000 distributors, super stockists, and sub-stockists** to strengthen category-specific distribution in OTC, pharma, and FMCG. - **E-commerce & Modern Trade:** - Listed on **Amazon, Flipkart, PharmEasy, Netmeds, BigBasket, and JioMart** - E-commerce sales surpassed **₹10 crore in FY23** - Own platforms: **World of Amrutanjan.com** and **Comfy app** (D2C, cycle tracking, private buying) - **Quick Commerce:** Emerged as a **fastest-growing channel**. - **D2C Stores:** ‘**World of Amrutanjan**’ experience stores launched in **Delhi and Chennai**, with national expansion planned. #### **7. Manufacturing & Compliance** - **OTC Units:** ISO 9001 certified, GMP and Drugs & Cosmetics Act compliant. - **Capacity:** 1,700 MT/year — sufficient for current demand. - **cGMP Allopathic Facility (Sep 2025):** Built to **USFDA OTC Monograph standards**; enables **exports to US and regulated markets**. - Products to be **registered with USFDA** - **Sustainability:** Focus on **reducing plastic use** and increasing green energy, though not yet core to business advantage. #### **8. International Expansion** - Exports to **13 countries** (Middle East, Africa, SE Asia, Asia) - **Dubai hub** for regional operations - Strategic intent to enter **US Amazon marketplace** with balm range - Partnered with a leading marketing agency to promote **Amrutanjan Relief** brand globally --- ### **Financial & Operational Highlights** - **Profitability:** Achieved **double-digit profit growth** driven by higher-margin pain management products and improved operational efficiency. - **Margin Goals:** Target **EBIT margin of 13%** (up from 10.8% in FY24). - **Operating Efficiency:** Digitized **60% of critical processes** via **SAP and sales force automation**. - Enterprise BI platform launched for real-time data analytics. - **Cost Optimization:** Focus on reducing **freight, packaging material costs**, and supply chain bottlenecks. --- ### **Challenges & Risks** - **Category Headwinds:** - Post-pandemic demand softness in **headache relief category** - ORS market pressure due to **mislabeling, competition, price wars** - **Market Penetration Gaps:** Low reach in **P3 markets** (rural, remote) - **Input Costs:** Rising prices of **packaging materials** - **Regulatory Changes:** May impact compliance and margins